News & Publications
Find our latest news and analysis here. From the daily Newsstand to the Quarterly Journal, we cover the full breadth of intellectual property law.
Written January 10, 2020
The US Court of Appeals for the Federal Circuit on January 7, 2020, vacated and remanded a lower court ruling which held that Amneal Pharmaceuticals LLC, an integrated specialty pharmaceutical company, didn’t infringe Amgen Inc.’s patent for the kidney disease drug Sensipar. Amgen Inc. v. Amneal Pharm., Fed. Cir., No. 16-853, 1/7/20.
Amgen, a biopharmaceutical company, sued Amneal, the Piramal Group, and Zydus Pharmaceuticals in an effort to block the three companies from bringing competing generic versions of their drug into the market.
The Federal Circuit affirmed the lower court’s ruling that Piramal’s product doesn’t infringe claims of the Amgen patent, while finding Zydus—which cross-appealed for its own generic product—is infringing the claims.
Amgen, a biopharmaceutical company, sued Amneal, the Piramal Group, and Zydus Pharmaceuticals in an effort to block the three companies from bringing competing generic versions of their drug into the market.
The Federal Circuit affirmed the lower court’s ruling that Piramal’s product doesn’t infringe claims of the Amgen patent, while finding Zydus—which cross-appealed for its own generic product—is infringing the claims.
Broadcast Opportunities
Looking for opportunities to get published? Submit your work to the AIPLA Quarterly Journal or AIPLA Innovate Magazine.
Exhibitor and Sponsorship Opportunities
Highlight your brand at a premier intellectual property law event, webinar, podcast, or in one of our publications.
For rates, availability, or additional details, click here or contact:
Meghan Donohoe
COO
American Intellectual Property Law Association (AIPLA)
T| +1.703.415.1343
E| mdonohoe@aipla.org